Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Harry L. A. Janssen"'
Autor:
Nicole S Erler, Robert J de Knegt, Jordan J Feld, Bettina E Hansen, Harry L A Janssen, Adriaan J van der Meer, Christoph Welsch, Stefan Zeuzem, Amy Puenpatom, Thomas Vanwolleghem, Robert A de Man, Lisette A P Krassenburg, Raoel Maan, Stijn van Hees, Orlando Cerrhoci, Johannes Vermehren
Publikováno v:
BMJ Open Gastroenterology, Vol 10, Iss 1 (2023)
Background and aims Historical paired liver biopsy studies are likely to underestimate current progression of disease in patients with chronic hepatitis C virus (HCV) infection. We aimed to assess liver disease progression according to the non-invasi
Externí odkaz:
https://doaj.org/article/20684bd7459a42a999c55f58c9c6cca6
Autor:
Adrian Kuipery, Deeqa Mahamed, Shirin Nkongolo, June Ann D’Angelo, Alexandra Johnson Valiente, Aman Mehrotra, William C. Chapman, Peter Horton, Ian McGilvray, Harry L. A. Janssen, Adam J. Gehring
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Background & AimMen have a higher prevalence of liver disease. Liver myeloid cells can regulate tissue inflammation, which drives progression of liver disease. We hypothesized that sex alters the responsiveness of liver myeloid cells, predisposing me
Externí odkaz:
https://doaj.org/article/52f8c305f1544d96b32472eb340000fc
Autor:
Harry L A Janssen, Jinlin Hou, Tarik Asselah, Henry L Y Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald G Nahass, Stefan Bourgeois, Maria Buti, Pietro Lampertico, Oliver Lenz, Thierry Verbinnen, Joris Vandenbossche, Willem Talloen, Ronald Kalmeijer, Maria Beumont, Michael Biermer, Umesh Shukla
Publikováno v:
Gut. BMJ Publishing Group
Scientia
Scientia
ObjectiveWe present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier:NCT03361956).Design232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f702b8cc4a17edfe62562c85466ffa3f
https://doi.org/10.1136/gutjnl-2022-328041
https://doi.org/10.1136/gutjnl-2022-328041
Autor:
Sara Ferrando-Martinez, Angie Snell Bennett, Elisabete Lino, Adam J. Gehring, Jordan Feld, Harry L. A. Janssen, Scott H. Robbins
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundA functional cure for chronic HBV could be achieved by boosting HBV-specific immunity. In vitro studies show that immunotherapy could be an effective strategy. However, these studies include strategies to enrich HBV-specific CD8 T cells, wh
Externí odkaz:
https://doaj.org/article/1d3c2b542cb748e982935aa50d7154cf
Autor:
William W. L. Wong, Petros Pechivanoglou, Josephine Wong, Joanna M. Bielecki, Alex Haines, Aysegul Erman, Yasmin Saeed, Arcturus Phoon, Mina Tadrous, Mona Younis, Noha Z. Rayad, Valeria Rac, Harry L. A. Janssen, Murray D. Krahn
Publikováno v:
Systematic Reviews, Vol 8, Iss 1, Pp 1-15 (2019)
Abstract Background Chronic hepatitis B (CHB) infection poses a significant burden to public health worldwide. Most cases are clinically silent until late in the disease course. The main goal of current therapy is to improve survival and quality of l
Externí odkaz:
https://doaj.org/article/b326f4300a34404db8ef0d8228e25d82
Autor:
Heiner Wedemeyer, Tammo L. Tergast, Jeffrey V. Lazarus, Homie Razavi, Kostas Bakoyannis, Ricardo Baptista‐Leite, Marco Bartoli, Philip Bruggmann, Cristian‐Silviu Buşoi, Maria Buti, Manuel Carballo, Laurent Castera, Massimo Colombo, Rodrigo Sousa Coutinho, Yuval Dadon, Gamal Esmat, Rafael Esteban, Joan Colom Farran, Mark Gillyon‐Powell, David Goldberg, Sharon Hutchinson, Harry L. A. Janssen, George Kalamitsis, Loreta A. Kondili, John S. Lambert, Rui Tato Marinho, Mojca Maticic, Aldo Patricello, Markus Peck‐Radosavljevic, Stanislas Pol, Mario Poljak, Cora Pop, Tomislov Sokol, Vana Sypsa, Nurdan Tözün, Zobair Younossi, Alessio Aghemo, George V. Papatheodoridis, Angelos Hatzakis
Publikováno v:
Liver International. 43(2):276-291
In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2993de5a978f0503ddc104c300947b
https://doi.org/10.1111/liv.15446
https://doi.org/10.1111/liv.15446
Autor:
Josef Wagner, Lilly Yuen, Margaret Littlejohn, Vitina Sozzi, Kathy Jackson, Ross Martin, Thomas Aeschbacher, Vithika Suri, Susanna K. Tan, Becket Feierbach, Anuj Gaggar, Patrick Marcellin, Maria Buti Ferret, Harry L. A. Janssen, Ed Gane, Niamh Meagher, David J. Price, Darren Wong, Alexander T. Thompson, Peter A. Revill
Publikováno v:
Alimentary Pharmacology & Therapeutics. 57:509-523
We investigated associations between hepatitis B virus (HBV) genome-length haplotype number (HN) at baseline in subjects with HBeAg-positive chronic hepatitis B (CHB), and the likelihood of achieving functional cure during direct-acting antiviral the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd9623a60cb0165e2e46622238bf079
https://doi.org/10.1111/apt.17299
https://doi.org/10.1111/apt.17299
Autor:
V. Stalin Raj, Gadissa Bedada Hundie, Anita C. Schürch, Saskia L. Smits, Suzan D. Pas, Sophie Le Pogam, Harry L. A. Janssen, Rob J. de Knegt, Albert D. M. E. Osterhaus, Isabel Najera, Charles A. Boucher, Bart L. Haagmans
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
Abstract Current standard-of-care treatment of chronically infected hepatitis C virus (HCV) patients involves direct-acting antivirals (DAA). However, concerns exist regarding the emergence of drug -resistant variants and subsequent treatment failure
Externí odkaz:
https://doaj.org/article/406c4163dec244f4a42d839b533621dc
Autor:
Alex S. Genshaft, Sonu Subudhi, Arlin Keo, Juan Diego Sanchez Vasquez, Nádia Conceição-Neto, Deeqa Mahamed, Lauke L. Boeijen, Nadia Alatrakchi, Chris Oetheimer, Mike Vilme, Riley Drake, Ira Fleming, Nancy Tran, Constantine Tzouanas, Jasmin Joseph-Chazan, Martin Arreola Villanueva, Harmen J. G. van de Werken, Gertine W. van Oord, Zwier M.A. Groothuismink, Boris J. Beudeker, Zgjim Osmani, Shirin Nkongolo, Aman Mehrotra, Kurt Spittaels, Jordan Feld, Raymond T. Chung, Robert J. de Knegt, Harry L. A. Janssen, Jeroen Aerssens, Jacques Bollekens, Nir Hacohen, Georg M. Lauer, Andre Boonstra, Alex K. Shalek, Adam J. Gehring
Publikováno v:
Hepatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2079272e3ba0acbf73b3fcc4a7b1b76
https://doi.org/10.1097/hep.0000000000000438
https://doi.org/10.1097/hep.0000000000000438
Autor:
Nehna Abdul Majeed, Ahmad Samer Alawad, Kin Seng Liem, Varun Takyar, Harvey Alter, Jordan J. Feld, Harry L. A. Janssen, Marc G. Ghany
Publikováno v:
Digestive Diseases and Sciences. Springer New York
Background and Aims: Hepatitis B virus (HBV) reactivation has been reported in patients co-infected with hepatitis C virus (HCV) during direct acting antiviral (DAA) therapy, leading the United States Food and Drug Administration (U.S. FDA) to issue
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2bd4bab6edd4f13f3156de30c16dec1
https://pure.eur.nl/en/publications/8a527b73-f343-4953-bd7b-cab23c7fc6f6
https://pure.eur.nl/en/publications/8a527b73-f343-4953-bd7b-cab23c7fc6f6
